• 
• 
• 

FDA News and Drug Updates

February 8, 2019 - FDA Approvals, News & Updates

February 1, 2019 - FDA Approvals, News & Updates

Adverse Effects

Understanding Immunotherapy Late Adverse Effects in Cancer Survivors

Meg Barbor, MPH

Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer

Adverse Events Associated with Checkpoint Inhibitors

Alice Goodman

View All Supportive Care Articles

Immunotherapy

Adding Immunotherapy to Chemotherapy Extends Survival in Metastatic Triple-Negative Breast Cancer

Phoebe Starr

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

Nivolumab–Ipilimumab Combination Highly Active in Metastatic MSI-H or dMMR Colorectal Cancer

View All Breast Cancer Articles

Conference Correspondent

Palliative Care Use Dismal Among Patients with Hematologic Malignancies

Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss

Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia

“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference

Silent Patients Find Their Voices Through an Advocate’s Journey

View All Conference Correspondent Articles

Most Popular Articles

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

JHOP Web Exclusives - Immunotherapy, Renal-Cell Carcinoma

Government Shutdown Impacts FDA Drug Approvals

In the News: Oncology - February 2019 - Breaking News, FDA Approvals, News & Updates

February 1, 2019 - FDA Approvals, News & Updates

In the News: Oncology - January 2019 - Breaking News, FDA Approvals, News & Updates

I. New Drugs

TOP - February 2019, Vol 12, No 1 - FDA Approvals, News & Updates

Avelumab plus Axitinib Combination Improves Outcomes in Advanced Renal-Cell Carcinoma

Wayne Kuznar

TOP - February 2019, Vol 12, No 1 - Immunotherapy, Renal-Cell Carcinoma